Navigation Links
ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report

ALBANY, New York, June 19, 2012 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

GBI Research, the leading business intelligence provider, has released its latest research, Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar, which provides insights into bone metabolic disease therapeutics until 2018.

To Browse Full TOC, Tables & Figures visit: 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. The report also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report also includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.

Related Market Research Reports on  Bone Market

Bone Cancer Pipeline Review

Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers

Bone Metastasis Global Clinical Trials Review

Bone Cancer Global Clinical Trials Review

Bone Graft Substitutes

ENT Devices Market

Bone Metastases Therapeutics - Pipeline Assessment

Bone and Joint Infection Market

Pagets disease of Bone

GBI Researchs analysis shows that the overall global bone metabolism therapeutics market for the four indications (which includes osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases) was valued at $15 billion in 2010, growing from $10.1 billion in 2002 and indicating a CAGR of 5.2%. GBI Research forecasts the market to grow at a CAGR of 7.7% between 2010 and 2018 to record a sales value of $27.1 billion by 2018. The growth in the bone metabolism therapeutics market is mainly due to the contribution of osteoporosis market. The revenue of osteoporosis market alone has approximately 68% of the total bone metabolism revenue. So, the global bone metabolism market is growing inspite of the declining market nature of the rest of therapeutics areas discussed here.


- Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2018 for the three indications osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in the global bone metabolism therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global bone metabolism therapeutics market, including top companies benchmarking. The key companies studied in this report are Amgen Inc., Abbott Laboratories, Genzyme Corporation, Merck & Co. Inc. and Novartis AG.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorders therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Report Category:


Browse All  GBI Research Latest Reports & Industry Analysis

Latest Reports by GBI Research

Pharmaceutical Pricing and Reimbursement in China

Emerging Pharmaceutical Market in South Africa

Translational Regenerative Medicine Market

Workforce Reductions in Pharmaceuticals

Re-evaluating Pharmaceutical Pipelines

Biological Strategies in the Emerging Markets

Negative Pressure Wound Therapy Market

Ambient Energy Harvesters Market

Pico Projectors Market

Acrylonitrile Global Market

Advanced Batteries Market

Emerging Pharmaceutical Market in Indonesia and Philippines

Polyethylene Terephthalate (PET) Global Market

Prescribing Trends in Opioids

Drug Price Cuts in Top Five Countries of Europe

Pricing and Reimbursement in Brazil

Generics in Cardiovascular Diseases Market

Antibacterials Market

Arthritis Therapeutics Market

Patient Perspectives

Coal Mining Market

Iron Ore Mining Market in Europe

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948

SOURCE ResearchMoz
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
2. ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share
3. ResearchMoz: MicroRNA Market Trends 2011
4. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
5. ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018
6. ResearchMoz: Vaccine Production Market (Trends, Techniques, Key Players, Spending Estimates and Forecasts)
7. Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
11. Fate Therapeutics Strengthens Its iPSC Platform
Post Your Comments:
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
Breaking Biology Technology:
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
(Date:10/23/2015)... Oct. 23, 2015 Research and Markets ( ... "Global Voice Recognition Biometrics Market 2015-2019" report to ... --> The global voice recognition biometrics market to ... --> --> The ... prepared based on an in-depth market analysis with inputs ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):